Department of Obstetrics and Gynecology, The First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.
College of Medicine, Nankai University, 94 Weijin Road, Tianjin, 300071, China.
Taiwan J Obstet Gynecol. 2023 Sep;62(5):729-734. doi: 10.1016/j.tjog.2023.07.016.
To investigate if next-generation sequencing-based preimplantation genetic testing for aneuploidies could improve pregnancy outcomes in women of advanced maternal age.
A retrospective analysis. The clinical data of 1099 couples treated in the First Medical Center of the Chinese PLA General Hospital from January 2019 to December 2021 were analyzed. They were divided into two groups based on whether they underwent a Next-generation sequencing-based preimplantation genetic test for aneuploidies. We analyzed and compared the biochemical pregnancy rate, clinical pregnancy rate, abortion rate, and live birth rate between the two groups.
The Preimplantation genetic testing for aneuploidies (PGT-A) group was associated with higher rate of biochemical pregnancy and clinical pregnancy than the non-PGT-A group, which were 63.9% vs. 56.4% (P = 0.009) and 54.4% vs. 45.6% (P < 0.001), respectively. The abortion rate was significantly lower in the PGT-A group compared to the non-PGT-A group (2.3% vs. 14.7%, P < 0.001). In addition, the live birth rate was significantly higher in the PGT-A group compared to the non-PGT-A group (52.1% and 30.9%, respectively, P < 0.001).
Next-generation sequencing-based preimplantation genetic testing for aneuploidies significantly improved the pregnancy outcomes in women of advanced maternal age.
研究基于新一代测序的胚胎植入前非整倍体检测是否能改善高龄产妇的妊娠结局。
回顾性分析。对 2019 年 1 月至 2021 年 12 月在中国人民解放军总医院第一医学中心接受治疗的 1099 对夫妇的临床数据进行分析。根据是否进行了基于新一代测序的胚胎植入前非整倍体检测，将他们分为两组。分析并比较两组之间的生化妊娠率、临床妊娠率、流产率和活产率。
胚胎植入前非整倍体检测（PGT-A）组的生化妊娠率和临床妊娠率均高于非 PGT-A 组，分别为 63.9%和 54.4%（P<0.001）和 56.4%和 45.6%（P=0.009）。PGT-A 组的流产率明显低于非 PGT-A 组（2.3%和 14.7%，P<0.001）。此外，PGT-A 组的活产率明显高于非 PGT-A 组（52.1%和 30.9%，P<0.001）。
基于新一代测序的胚胎植入前非整倍体检测显著改善了高龄产妇的妊娠结局。
